ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Alveolar macrophage-neutrophil crosstalk in acute lung injury: mechanisms, feedback loops, and therapeutic opportunities.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAcute lung injury (ALI) is a life-threatening condition characterized by dysregulated pulmonary inflammation and high mortality rates. Alveolar macrophages and neutrophils are central innate immune cells that orchestrate the inflammatory response in injured lungs. Accumulating evidence indicates that dynamic interactions between these two cell types play a pivotal role in ALI progression; however, the underlying regulatory mechanisms remain insufficiently understood.
objectiveThis review aims to comprehensively analyze themolecular and cellular processes governing the communication between alveolar macrophages and neutrophils in ALI and to discuss emerging therapeutic strategies targeting this cell-cell interaction, with the goal of providing insights into novel biomarkers and therapeutic targets for ALI.
methodsA comprehensive review of the relevant literature was conducted to summarize the molecular and cellular mechanisms underlyingalveolar macrophage-neutrophil crosstalk in ALI, including cytokine/chemokine signaling, pattern recognition receptor activation, inflammasome pathways, reactive oxygen species-mediated regulation, and neutrophil extracellular trap formation. In addition, therapeutic strategies targeting these interactions were collated and analyzed.
resultsAlveolar macrophage-neutrophil communication in ALI is mediatedby multiple pathways, including cytokine and chemokine signaling, pattern recognition receptor activation, inflammasome activation, reactive oxygen species regulation, and neutrophil extracellular trap (NET) formation. Bidirectional feedback loops exist between the two cell types,where they either amplify or limit each other's activities depending on the pathological state, thereby regulating the balance between host defense and tissue damage. Emerging therapeutic strategies targeting this crosstalk, such as the modulation of macrophage inflammatory phenotypes, inhibition of neutrophil recruitment, and prevention of neutrophil extracellular trap formation, show promising translational potential for restoring immune homeostasis in ALI.
conclusionAlveolar macrophage-neutrophil crosstalk constitutes a critical regulatory axisin ALI pathogenesis. Elucidating the mechanisms and feedback networks of this interaction is essential for identifying novel biomarkers and therapeutic targets, which will facilitate the development of more precise and effective immunomodulatory treatments for ALI.
Indexed as
Identifiers
42154058What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.